TODAY'S DISCUSSION ---IF CORTEX DAMAGED?
YESTERDAY WE DISCUSSED NON IMPLANT VISION FOR BLiND
=====================================================================
Short answer: if the visual cortex is destroyed, a cortical “display” (implant or ultrasound) has little to write to, but there are several fallback routes. I’m answering from established research, not a fresh literature search, so treat the newest trial results as unchecked.
1. Can another brain area take over?
- Hearing and touch areas (the main route). The brain already does this. In people blind from early life, the occipital cortex is recruited for Braille, hearing and language. Sensory substitution devices (tongue-grid, sound-to-image) activate it in blind users. If the occipital cortex is destroyed, the same devices still work through auditory and touch cortex. This is why your Stages 1 and 2 don’t depend on the visual cortex at all.
- Other visual areas. Stimulating areas beyond V1 (V2, V3, motion area MT) can also evoke phosphenes. The research is thin, but it is the logical target when V1 is lost and the later areas survive.
- Pathways that bypass V1. Some people with V1 damage show “blindsight”. They can detect motion or location without conscious seeing, via routes through the midbrain and thalamus. It is real but crude, and not yet usable as vision.
2. Can damaged cortex be revived?
Dead neurons can’t be revived. Recovery comes from surviving tissue and rewiring. Current approaches:
- Visual restitution/training therapy: repeated stimulation at the edge of the damaged field. Evidence is modest and debated.
- TMS or tDCS combined with training: aims to boost plasticity. Results are mixed and not standard care.
- Stem cell or neural graft repair of cortex: animal work only so far.
- Gene therapy and optogenetics: these are retinal, so they help eye and retina disease, not cortical damage.
- Timing: most spontaneous recovery after stroke or injury happens in the first few months.
3. Other options
- Thalamic (LGN) stimulation is explored in animals as a way to feed signals in before V1, but it fails if the damage is in the thalamus or the downstream pathway.
- Partial damage is far more common than total loss. The first step would be mapping what remains, which fits your phosphene-mapping idea.
What this means for your concept note
- Stage 3 only applies to people with a responsive visual cortex. Even long-term early-blind people often get no phosphenes, because the cortex has been repurposed.
- The pasted figures (148 million, “35–43 million with intact cortex”, “15–25 million untreatable”) came from another AI with unchecked citations. I wouldn’t send them to researchers without verifying them against WHO/IAPB sources.
- A stronger framing is three patient groups: eye/optic nerve damage with a healthy cortex (the Stage 3 candidates), cortical damage (substitution through hearing and touch), and partial damage (hybrid).
Would you like me to search for the latest human trials on extrastriate and thalamic stimulation and on cortical stroke rehabilitation, so the note can cite them?
====================================================================
1==search for the latest human trials on extrastriate and thalamic stimulation and on cortical stroke rehabilitation, so the note can cite them?
==========================================
2==Stem cell or neural graft repair of cortex: animal work only so far.
====================================================================
3==my main interest is today:-
- Pathways that bypass V1. Some people with V1 damage show “blindsight”. They can detect motion or location without conscious seeing, via routes through the midbrain and thalamus. It is real but crude, and not yet usable as vision.
including :-extrastriate and thalamic stimulation
====================================================================
I found no human trial yet that stimulates the thalamus or extrastriate cortex to restore vision. I also need to correct one thing I told you earlier.
Correction: stem cells and grafts. I said this was animal work only. That was incomplete, because early human trials do exist, but they are for motor stroke, not visual cortex. A Lausanne pilot study (AVCell) plans to re-implant a patient’s own cortical tissue grown from a biopsy. It is a feasibility and safety study in stroke patients with motor deficits, and the page I found lists it as not yet enrolling. A Phase 2b trial of an allogeneic neural stem cell product, CC-101, is also planned. It is listed as not yet recruiting, with 36 participants, a January 2027 start, and the cells placed next to the stroke lesion to improve motor recovery. The most recent preclinical paper I found was a January 2026 mouse study, in which human stem-cell-derived neurons survived, integrated into circuits and restored function in stroke-injured mice. I found nothing for visual cortex repair in humans. study of the therapeutic effects of cortical autograft implantation in patients with cerebral ischem +2
1. Thalamic (LGN) stimulation: animal stage, with funding in place
- The VA Boston project proposes an LGN prosthesis, partly because the LGN lies beyond the damage seen in most causes of blindness, and its signalling is less abstract than cortex. Their early tests found that LGN stimulation drives downstream visual circuits and also activates V1. ai-analyticsai-analytics
- Rice University has an NIH grant to implant ultraflexible electrodes in the LGN, but most of the work is in animal models, and it is not a trial enrolling patients. findatrial
- Older foundational work shows the principle. A rat study found that LGN stimulation can produce V1 responses resembling those from natural visual stimuli. A monkey study used the animals’ habit of looking at a light to test what LGN stimulation produces (they are treated like points of light). nihnih
- Pieter Roelfsema is scheduled to speak on “Towards a thalamic visual prosthesis: electrical and optogenetic approaches” at the 2026 Brain & Chip conference, which suggests the field is still at the “towards” stage. umh
2. Extrastriate stimulation: little human phosphene evidence
- Human work mostly shows disruption, not seeing. One epilepsy-patient study found that focal electrical stimulation in the posterior temporal lobe impaired motion perception in one direction only. jci
- The prosthesis case is made from monkeys. In macaque V4, combined responses from multiple sites could discriminate spatial positions, suggesting patterned stimulation might localize points there. paperswithcode
- The benefit would be that extrastriate cortex covers a large part of the visual field with less tissue, but this is a hypothesis, not a result. paperswithcode
3. Blindsight pathways (your main interest)
- The best human evidence is Ajina et al. (eLife, 2015). In 17 patients with V1 damage, every blindsight-positive patient had an intact LGN-to-hMT+ pathway, while it was impaired or unmeasurable in those without blindsight. The superior colliculus route was not consistently present. elifesciences
- Monkey work points elsewhere. Kinoshita et al. (Nature Communications, 2019) found that blocking the superior colliculus to pulvinar pathway impaired eye movements to targets in the blind field. springer
- A review notes that the superior colliculus is widely accepted as important, while the LGN versus pulvinar relay remains debated. Early-life damage seems to help: patient GY’s early injury, when reorganisation was still possible, may explain his extensive blindsight. nihuni-giessen
- These studies explain residual unconscious function. None shows that stimulating these routes produces usable vision.
4. Cortical stroke rehabilitation: the most citable human result
- Raffin et al., Brain, December 2025, was a double-blind, randomized crossover trial of 16 stroke patients. Stimulation that promoted feedforward input from V1 to the motion area (MT) improved motion discrimination and shifted visual field borders. nih
- The effect was strongest in patients whose V1-to-MT pathways were still partly intact. That fits your point about bypass pathways. medicaldialogues
- This is a small study, and the authors say larger trials are needed. A Wake Forest trial of multisensory training, with 72 planned participants, is listed as about to begin enrolling. veeva
What this means for your note
- You could add a fourth patient group, “damaged V1, intact LGN-to-MT route”, with the Ajina finding and the Raffin trial as citations. Both are real and checkable.
- The trial pages I found are aggregator summaries, so please verify each ID on clinicaltrials.gov before citing.
- A speculative idea I’d label as such: focused ultrasound can reach deeper targets than TMS, so testing whether it can modulate the LGN-to-MT pathway is a fair question for researchers. I found no evidence yet.
Would you like me to draft this as a short “patients with V1 damage” section for the concept note?
No comments:
Post a Comment